1. Home
  2. KRUS vs PRME Comparison

KRUS vs PRME Comparison

Compare KRUS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$48.20

Market Cap

539.2M

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.16

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
PRME
Founded
2008
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.2M
536.4M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
KRUS
PRME
Price
$48.20
$3.16
Analyst Decision
Buy
Buy
Analyst Count
9
6
Target Price
$81.11
$7.56
AVG Volume (30 Days)
222.8K
2.8M
Earning Date
04-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
18.18
EPS
N/A
N/A
Revenue
$282,763,000.00
$4,632,000.00
Revenue This Year
$20.50
$7.06
Revenue Next Year
$20.68
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
18.88
55.28
52 Week Low
$42.62
$2.67
52 Week High
$87.99
$6.94

Technical Indicators

Market Signals
Indicator
KRUS
PRME
Relative Strength Index (RSI) 49.67 49.85
Support Level $47.15 $3.16
Resistance Level $50.25 $3.60
Average True Range (ATR) 1.92 0.18
MACD 0.43 0.01
Stochastic Oscillator 74.48 74.79

Price Performance

Historical Comparison
KRUS
PRME

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: